Γ—

Diagnosing Alzheimer’s in the Near Infrared

Some light wavelengths can pass through tissues.

Share







Near IRNear IR

In Nature Biomedical Engineering, a team of researchers has published an innovative method of making tau tangles and amyloid beta visible in the near infrared, allowing doctors and researchers to see through bone with relatively simple equipment.

To do this, we need your support. Your charitable contribution tranforms into rejuvenation research, news, shows, and more. Will you help?

Current methods are difficult

There are three main approaches to diagnosing Alzheimer’s and other brain disorders in living people: magnetic resonance imaging (MRI) [1], positron emission tomography (PET) [2], and single-photon emission computed tomography (SPECT) [3]. Unfortunately, all three require bulky and expensive equipment. An MRI creates a substantial magnetic field and can’t be safely performed on someone with metallic objects in the body, while both PET and SPECT scans involve radioactive tracers.

It would be ideal if tau tangles and amyloid plaques could simply be viewed optically. While this appears impossible, prior work had explored the idea, developing phosphorescent compounds that attach themselves to the characteristic amyloids of Alzheimer’s [4]. This runs into an obvious problem: how would it be possible to see this glow through the skull and scalp?

While mammalian tissue blocks the visible spectrum, it is much more transparent to near-infrared light. Other researchers have explored this idea, developing phosphorescent proteins for potential use in diagnostics [5]. However, this paper is the first of its kind in developing a method to attach such near-infrared phosphors to Alzheimer’s amyloids in living animals.

An improvement over previous compounds

This paper investigates the new compound ZW800-1C, which is structurally similar to the FDA-approved ICG and is closely related to a previously developed compound, ZW800-1A.

In an ex vivo examination, ICG was found to bind almost exactly as well to amyloid beta plaques as ThioS, an established compound that emits violet light. However, in a transgenic mouse model, ICG failed to bind to in vivo plaques and did not bind well to signs of cerebral amyloid angiopathy (CAA), another sign of Alzheimer’s disease. The researchers hypothesize that this is because it failed to cross the blood-brain barrier. It also has a relatively short half-life in blood.

ZW800-IA fared little better as a potential diagnostic. Ex vivo, it did not clearly bind to amyloid at all, and in vivo, its visibility was muted for both plaques and CAA.

ZW800-IC was much more effective. It rapidly bound to amyloid, and it was found to be very visible in ex vivo and in vivo models, including both plaques and CAA. It was better distributed in tissue, lasted longer in blood, and, most importantly, was found to be reactive with tau pathology, a trait not shared by either of the other two compounds.

ZW800-1C

Fluorescent compounds such as these only emit photons when they are struck by photons; the amount of time between absorption and emission is known as its lifetime, which is measured in picoseconds for ZW800-IC. This lifetime was found to vary between blood vessels, amyloid plaques, CAA, and tau tangles. Additionally, its emission was in different wavelengths depending on its attachment to AΞ²40 or AΞ²42, two variants of amyloid beta. These distinctions are potentially valuable in diagnosing Alzheimer’s.

Conclusion

This paper concludes with a key observation. As humans are much larger than mice and there is much more tissue to penetrate, using targeted photons to activate fluorescent proteins for microscopically close examination is infeasible. A more scattered, generalized approach would have to be used instead. However, if the lifetime or spectrum of the fluorescence are different, as they have been shown to be in this study, those details could be useful biomarkers for Alzheimer’s pathology and potentially help in the early diagnosis of Alzheimer’s disease.

This approach might also be of considerable use for researchers who are using mouse models to develop therapies against Alzheimer’s and tauopathies. In many cases, examining the brains of living animals through the intact skull, as opposed to cranial windows or euthanasia-based approaches, is likely to save money, time, and animals.

We would like to ask you a small favor. We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. We are committed to responsible journalism, free from commercial or political influence, that allows you to make informed decisions about your future health.

All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future. You can support us by making a donation or in other ways at no cost to you.

Study: Waist-to-Hip Ratio Predicts Mortality Better Than BMI

A new study suggests that waist-to-hip ratio (WHR) has a more linear correlation with all-cause mortality than either body mass...

Restoring Heart Regeneration With a Metabolic Switch

In a recent article in Nature, researchers have restored cardiac regeneration to adult mice by disabling fatty acid oxidation, discovering...

Human Clinical Trials of NMN for Safety and Effectiveness

In a recent paper, researchers reviewed the literature for human clinical trials that address NMN's safety and anti-aging effects [1]....

Lifespan News – Elon Musk and the Living Forever Curse

On this episode of Lifespan News, Ryan O'Shea ruminates on Elon Musk's statement on living forever being a curse rather...

Literature

[1] Poduslo, J. F., Wengenack, T. M., Curran, G. L., Wisniewski, T., Sigurdsson, E. M., Macura, S. I., … & Jack Jr, C. R. (2002). Molecular targeting of Alzheimer’s amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiology of disease, 11(2), 315-329.

[2] Mathis, C. A., Mason, N. S., Lopresti, B. J., & Klunk, W. E. (2012, November). Development of positron emission tomography Ξ²-amyloid plaque imaging agents. In Seminars in nuclear medicine (Vol. 42, No. 6, pp. 423-432). WB Saunders.

[3] Valotassiou, V., Malamitsi, J., Papatriantafyllou, J., Dardiotis, E., Tsougos, I., Psimadas, D., … & Georgoulias, P. (2018). SPECT and PET imaging in Alzheimer’s disease. Annals of nuclear medicine, 32, 583-593.

[4] Heo, C. H., Sarkar, A. R., Baik, S. H., Jung, T. S., Kim, J. J., Kang, H., … & Kim, H. M. (2016). A quadrupolar two-photon fluorescent probe for in vivo imaging of amyloid-Ξ² plaques. Chemical science, 7(7), 4600-4606.

[5] Shcherbakova, D. M., Stepanenko, O. V., Turoverov, K. K., & Verkhusha, V. V. (2018). Near-infrared fluorescent proteins: multiplexing and optogenetics across scales. Trends in biotechnology, 36(12), 1230-1243.

CategoryNews
About the author
Josh Conway

Josh Conway

Josh is a professional editor and is responsible for editing our articles before they become available to the public as well as moderating our Discord server. He is also a programmer, long-time supporter of anti-aging medicine, and avid player of the strange game called β€œreal life.” Living in the center of the northern prairie, Josh enjoys long bike rides before the blizzards hit.
No Comments
Write a comment:

*

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.